Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Bumble Inc (BMBL) Price & Performance

Amphastar Pharmaceuticals IncTrade
Bumble IncTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Bumble Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Bumble Inc trades at $2.77 (market cap $359.61M). The key difference: Amphastar Pharmaceuticals Inc is far larger — about 2.4× Bumble Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Bumble Inc nearer its low. Which is the better fit depends on your goals.

AMPHBMBL
Market Cap
$863.95M$359.61M
Sector
HealthTechnology
52-Week High
$30.81$7.17
52-Week Low
$16.87$2.70
Enterprise Value
$1.26B$665.47M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Bumble Inc

Bumble (BMBL) trades at $2.83, down 0.53% with bearish technical signals. The company reported mixed Q2 2026 results, beating earnings estimates but missing on revenue with declining paying users. Despite a gross margin of 72.84%, Bumble shows negative profitability metrics with -57.96% net margin and -87.65% ROE. Recent news indicates strategic shifts toward IRL events and AI matchmaking amid exploration of potential sale options.

Outlook remains challenging with significant execution risks. While valuation multiples appear attractive (P/S 0.39, P/B 0.72), persistent user declines and negative cash flow create headwinds. Analyst consensus leans Hold (73.91%) with $3.62 price target suggesting 28% upside, but success hinges on product transformation reversing user trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Bumble Inc

Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.

Read more on BMBL